Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 Jul 25.

Published in final edited form as: J Natl Compr Canc Netw. 2019 Jul 1;17(7):813–820. doi: 10.6004/jnccn.2018.7281

Table 2:

Imaging and Serum Tumor Biomarker Use During the Peri-diagnostic Period

	All Women n=2,923	Stage (0-IIa) n=2,561	Stage (IIb+) n=362
No Advanced Imaging Use	2508 (85.8%)	2306 (90.0%)	202 (55.8%)
Advanced Imaging Use^a	415 (14.2%)	255 (10.0%)	160 (44.2%)
Bone Scan	134 (4.6%)	77 (3.0%)	57 (15.7%)
CT	289 (9.9%)	182 (7.1%)	107 (29.6%)
PET – CT	205 (7.0%)	101 (3.9%)	104 (28.7%)
Serum tumor biomarker Use	388 (13.3%)	287 (11.2%)	101 (27.9%)

^(a)

Including any combination of Bone Scan, CT, or PET-CT and/or imaging